Cargando…
Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543186/ https://www.ncbi.nlm.nih.gov/pubmed/37345488 http://dx.doi.org/10.3324/haematol.2023.283120 |
| _version_ | 1785114244545511424 |
|---|---|
| author | Swaminathan, Mahesh Ravandi, Farhad |
| author_facet | Swaminathan, Mahesh Ravandi, Farhad |
| author_sort | Swaminathan, Mahesh |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10543186 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105431862023-10-03 Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? Swaminathan, Mahesh Ravandi, Farhad Haematologica Editorial Fondazione Ferrata Storti 2023-06-22 /pmc/articles/PMC10543186/ /pubmed/37345488 http://dx.doi.org/10.3324/haematol.2023.283120 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Editorial Swaminathan, Mahesh Ravandi, Farhad Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? |
| title | Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? |
| title_full | Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? |
| title_fullStr | Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? |
| title_full_unstemmed | Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? |
| title_short | Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? |
| title_sort | can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543186/ https://www.ncbi.nlm.nih.gov/pubmed/37345488 http://dx.doi.org/10.3324/haematol.2023.283120 |
| work_keys_str_mv | AT swaminathanmahesh canmeasurableresidualdiseaseassessmentbereliablyusedtodeferallogeneicstemcelltransplantinpatientswithintermediateriskacutemyeloidleukemia AT ravandifarhad canmeasurableresidualdiseaseassessmentbereliablyusedtodeferallogeneicstemcelltransplantinpatientswithintermediateriskacutemyeloidleukemia |